What regulation shall we have for the operation? Shall a man transfuse he knows not what. to correct he knows not what. God knows how (l)? Dr. Henry Stubbs Royal College of Physicians circa 1670 If dialysis therapy were a new phannaceutical product being evaluated by the FDA now, it might not be approved for marketing. The recommended dose, its potential toxicity, the side effects of under-or over-dialysis as well as its efficacy have been the subject of very few studies. The high mortality rate associated with the treatment may raise a few eyebrows. That it is a life-saving modality of…mehr
What regulation shall we have for the operation? Shall a man transfuse he knows not what. to correct he knows not what. God knows how (l)? Dr. Henry Stubbs Royal College of Physicians circa 1670 If dialysis therapy were a new phannaceutical product being evaluated by the FDA now, it might not be approved for marketing. The recommended dose, its potential toxicity, the side effects of under-or over-dialysis as well as its efficacy have been the subject of very few studies. The high mortality rate associated with the treatment may raise a few eyebrows. That it is a life-saving modality of treatment is undoubtedly true for more than 100,000 patients in the United States and for more than a million patients world wide. Because dialysis has extended the lives of many people by a variable period of time, most nephrologists have "rested on their laurels" and did not vigorously pursue studies to optimize these treatments. But facts have a way of intruding in all our lives and the facts are that the overall mortality rate of dialysis patients in the United States is rising and stands close to 25% per year and is closer to 33% per year for patients between the ages of 65 and 74 (2). These mortality figures are considerably higher for age-adjusted dialysis populations in Europe and particu larly in Japan, and certainly for the age-adjusted nonnal population.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
1. Uremic Toxins & Dialysis.- The uremic syndrome.- Role of protein nitrogen metabolism.- Clinical measurement of uremia.- Effect of dialysis on the uremic syndrome.- Proposed uremic toxins.- Alternatives to the single-toxin theory.- Protein and tissue binding of proposed uremic toxins.- Toxic contributions of dialysis itself.- Where urea fits into the toxin theories.- 2. Urea Metabolism: Clinical Chemistry of Urea.- Excretion of nitrogenous waste products: comparative physiology.- Biochemistry of urea.- Inborn errors of urea metabolism: urea cycle enzymopathies.- Urea transport.- Nitrogen recycling.- Methods of urea measurement.- The toxicity of urea.- 3. Urea Modeling: Introduction.- Definition of modeling.- Evolution of urea modeling.- Why urea instead of other solutes?.- Quantifying hemodialysis therapy.- Quality assurance programs and urea modeling.- Urea modeling development and techniques.- What is the purpose of urea modeling?.- Urea modeling for high-flux, short-duration dialysis.- What clinical data are provided by urea modeling?.- Significance of the urea distribution volume (V).- Significance of the urea nitrogen generation rate (G).- Components of the dialysis prescription.- Measures of prescription effectiveness.- 4. Single-Compartment Model.- Models for hemodialysis urea kinetics.- Overview of kinetic analysis.- Laws of diffusion.- First-order kinetics: clearance, rate constant, half-life, and exponential decline.- The single-compartment model.- Constant-volume model, three BUN measurements.- Evaluation of the constant-volume model.- Variable-volume model, three BUN measurements.- Source code for the variable-volume model, three BUN values.- Two-BUN method, variable volume.- Comparison of the two-BUN method with the three-BUN method.- Source code for thevariable-volume model, two BUN values.- 5. Multicompartment Models.- Urea compartments in normal humans.- Limitations of the single-compartment model.- Description of the two-compartment model.- Site of urea generation.- Postdialysis rebound in urea concentration.- Two-compartment modeling techniques.- Solutions to equations for the two-compartment model.- Graphic description of the two-compartment model.- High-flux dialysis and two compartments.- Solutes with low mass transfer coefficients.- Measuring the intercompartment mass transfer area coefficient.- A comparison of one-compartment with two-compartment models.- The direct quantification method.- Impact of pool number on calculated variables.- Determinants of postdialysis urea rebound.- Two-compartment model with variable ECF volume.- Two-compartment model with variable ECF and ICF volume.- The magnitude of intracellular swelling.- Additional compartments.- Recommendations regarding modeling with one versus two compartments.- Blood sampling techniques and precautions.- 6. A Practical Solution: Ureakin.- Value of the computer program.- Description of the program.- Theoretical basis for the program.- Conventions and assumptions.- Files and file extensions used by UREAKIN.- Options available from the main menu.- Refinements to UREAKIN.- 7. Refinements and Application of Urea Modeling.- Measuring blood urea concentrations.- Compensation for blood and plasma water content.- Dialyzer urea clearance.- Effect of fluid balance on kinetic measurements.- Recirculation of dialyzer venous blood.- Residual (native kidney) urea clearance: its significance.- Simplified methods for urea modeling.- 8. Measuring Dialysis: How Much is Enough?.- Historical methods.- Kt/V: A yardstick for dialysis therapy.- Measuring dialysis outcome.- The adequacy of dialysis.- Comparing dialysis outcome with the prescription.- 9. Examples of Urea Modeling.- Case 1: Expected results in an average adult patient.- Case 2: A case with no residual function and no weight gain between dialyses; the effect of changing Kd..- Case 3: The patient with significant residual renal function (Kr).- Case 4: Effects of habitually large weight gains between dialyses.- Case 5: The patient with high protein intake.- Case 6: The patient with low protein intake.- Case 7: The patient treated with high-flux dialysis.- Case 8: The patient whose dialyzer clearance (Kd) varies from the expected clearance.- Case 9: Small patients and the pediatric patient.- 10. The Future.- Dialysis versus other treatments for end-stage renal failure.- Outcome parameters for high-flux dialysis.- More complex models.- Modeling other solutes.- Better markers for uremia.- Improved blood flow monitoring.- Dialysate modeling.- Real-time monitoring of urea kinetics.- Urea modeling from the total-care perspective.- Appendicies.- Appendix A. Source code for a single-compartment, variable-volume model: three-BUN method.- Appendix B. Source code for a single-compartment, variable-volume model: two-BUN method.- Appendix C. Source code for a two-compartment, fixed-volume model.- Appendix D. Numerical solution for a two-compartment, variable-ECV model.- Appendix E. Description of a two-compartment, osmotic model with variable ECV and ICV.- Appendix F. Interpreting the results of urea modeling.- Appendix G. Useful equations.- Appendix H. Examples of data collection forms.- Appendix I. Examples of modeling reports.
1. Uremic Toxins & Dialysis.- The uremic syndrome.- Role of protein nitrogen metabolism.- Clinical measurement of uremia.- Effect of dialysis on the uremic syndrome.- Proposed uremic toxins.- Alternatives to the single-toxin theory.- Protein and tissue binding of proposed uremic toxins.- Toxic contributions of dialysis itself.- Where urea fits into the toxin theories.- 2. Urea Metabolism: Clinical Chemistry of Urea.- Excretion of nitrogenous waste products: comparative physiology.- Biochemistry of urea.- Inborn errors of urea metabolism: urea cycle enzymopathies.- Urea transport.- Nitrogen recycling.- Methods of urea measurement.- The toxicity of urea.- 3. Urea Modeling: Introduction.- Definition of modeling.- Evolution of urea modeling.- Why urea instead of other solutes?.- Quantifying hemodialysis therapy.- Quality assurance programs and urea modeling.- Urea modeling development and techniques.- What is the purpose of urea modeling?.- Urea modeling for high-flux, short-duration dialysis.- What clinical data are provided by urea modeling?.- Significance of the urea distribution volume (V).- Significance of the urea nitrogen generation rate (G).- Components of the dialysis prescription.- Measures of prescription effectiveness.- 4. Single-Compartment Model.- Models for hemodialysis urea kinetics.- Overview of kinetic analysis.- Laws of diffusion.- First-order kinetics: clearance, rate constant, half-life, and exponential decline.- The single-compartment model.- Constant-volume model, three BUN measurements.- Evaluation of the constant-volume model.- Variable-volume model, three BUN measurements.- Source code for the variable-volume model, three BUN values.- Two-BUN method, variable volume.- Comparison of the two-BUN method with the three-BUN method.- Source code for thevariable-volume model, two BUN values.- 5. Multicompartment Models.- Urea compartments in normal humans.- Limitations of the single-compartment model.- Description of the two-compartment model.- Site of urea generation.- Postdialysis rebound in urea concentration.- Two-compartment modeling techniques.- Solutions to equations for the two-compartment model.- Graphic description of the two-compartment model.- High-flux dialysis and two compartments.- Solutes with low mass transfer coefficients.- Measuring the intercompartment mass transfer area coefficient.- A comparison of one-compartment with two-compartment models.- The direct quantification method.- Impact of pool number on calculated variables.- Determinants of postdialysis urea rebound.- Two-compartment model with variable ECF volume.- Two-compartment model with variable ECF and ICF volume.- The magnitude of intracellular swelling.- Additional compartments.- Recommendations regarding modeling with one versus two compartments.- Blood sampling techniques and precautions.- 6. A Practical Solution: Ureakin.- Value of the computer program.- Description of the program.- Theoretical basis for the program.- Conventions and assumptions.- Files and file extensions used by UREAKIN.- Options available from the main menu.- Refinements to UREAKIN.- 7. Refinements and Application of Urea Modeling.- Measuring blood urea concentrations.- Compensation for blood and plasma water content.- Dialyzer urea clearance.- Effect of fluid balance on kinetic measurements.- Recirculation of dialyzer venous blood.- Residual (native kidney) urea clearance: its significance.- Simplified methods for urea modeling.- 8. Measuring Dialysis: How Much is Enough?.- Historical methods.- Kt/V: A yardstick for dialysis therapy.- Measuring dialysis outcome.- The adequacy of dialysis.- Comparing dialysis outcome with the prescription.- 9. Examples of Urea Modeling.- Case 1: Expected results in an average adult patient.- Case 2: A case with no residual function and no weight gain between dialyses; the effect of changing Kd..- Case 3: The patient with significant residual renal function (Kr).- Case 4: Effects of habitually large weight gains between dialyses.- Case 5: The patient with high protein intake.- Case 6: The patient with low protein intake.- Case 7: The patient treated with high-flux dialysis.- Case 8: The patient whose dialyzer clearance (Kd) varies from the expected clearance.- Case 9: Small patients and the pediatric patient.- 10. The Future.- Dialysis versus other treatments for end-stage renal failure.- Outcome parameters for high-flux dialysis.- More complex models.- Modeling other solutes.- Better markers for uremia.- Improved blood flow monitoring.- Dialysate modeling.- Real-time monitoring of urea kinetics.- Urea modeling from the total-care perspective.- Appendicies.- Appendix A. Source code for a single-compartment, variable-volume model: three-BUN method.- Appendix B. Source code for a single-compartment, variable-volume model: two-BUN method.- Appendix C. Source code for a two-compartment, fixed-volume model.- Appendix D. Numerical solution for a two-compartment, variable-ECV model.- Appendix E. Description of a two-compartment, osmotic model with variable ECV and ICV.- Appendix F. Interpreting the results of urea modeling.- Appendix G. Useful equations.- Appendix H. Examples of data collection forms.- Appendix I. Examples of modeling reports.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
